In this edition of AI Prognosis: Quirky medical data tripping up sepsis algorithms, AI scribes for patients, and some AI biotech news.

A new analysis found the average drug shortage in 2025 had lasted 5.3 years, exceeding the 4.3 years seen in 2024

Drug pricing in Europe, AI deals for VC firms, and more biotech news from The Readout

The American College of Obstetricians and Gynecologists has released a recommended vaccine schedule during pregnancy, one that diverges from CDC guidance.

A new era of American sunscreen, NIAID taps new acting director, and more health news from Morning Rounds

The Trump administration has warned more than 500 hospitals that they are failing to provide the public with basic pricing information.

Federal health regulators on Tuesday signed off on the first new sunscreen ingredient for the U.S. market in more than 25 years.

AstraZeneca's GLP-1 pill, GSK's $10.6B cancer startup acquisition, and more biotech news from The Readout

The condemnations keep coming after five diabetes experts were escorted out of an ADA meeting for handing out copies of an editorial criticizing federal research cuts.

The number of prescription drug shortages in the U.S. fell by 23% last year, but a new analysis found other troubling signs about medicines in short supply.

Plus a buried alcohol study gets published, and a Biosecure update.

Federal actions and proposals have reignited debate over methadone and buprenorphine, worrying addiction experts and patient groups.

In Europe, two divergent paths are emerging as countries grapple with what to do about drug prices, affecting both pharma and patients — and testing the influence of the U.S.

“Legal protection for abortion does not mean equitable access for minors,” a pediatrics resident writes.

“I know what I’m getting into”: Dawn Zuidgeest-Craft on starting medical residency at almost 73.

“Innovations like xenotransplantation would never have reached clinical trials without animal experimentation,” writes transplant surgeon Joshua Mezrich.

Wearables generate a lot of health data, but it exists outside the clinic for the most part. New moves from Oura and Whoop may change that.

Is it “health care” or “healthcare”? STAT readers had strong feelings.

Hospital execs say they're working to mitigate the impacts of the looming cuts.

As the world deals with an outbreak of Ebola that has no known cure, Susan Reichle, who last year co-founded Aid Transition Alliance to support former USAID professionals, discusses the…

Revolution and Tango yield promising cancer results, Incyte buys bleeding disorder drug, and more biotech news

A combination of pancreatic cancer drugs from Tango Therapeutics and Revolution Medicines led to a strong response rate in an early-stage trial.

Why "Schedule F" matters, the Ebola outbreak response, and more health news from Morning Rounds

Lilly disclosed new data that provide more details on the safety and tolerability of its next-generation obesity drug retatrutide

The biggest U.S. health insurer is changing how it pays for lactation counseling, and it could cut payment for many providers.

Johnson & Johnson said it will purchase the startup Firefly Bio for $1 billion in an effort to expand its work in the suddenly buzzy field of KRAS inhibitors.

AstraZeneca’s GLP-1 pill showed promise in mid-stage obesity and diabetes studies, but it may still be too early to determine how it stacks up against other oral treatments.

Health workers at the epicenter of Congo's Ebola outbreak are laboring with little pay or rest.

A government-commissioned study had been meant to inform new dietary guidelines, and found risks associated with even light drinking.

GSK is buying Nuvalent, the maker of targeted cancer drugs, for $10.6 billion, a sizable addition to the latest run of biopharma acquisitions.